Every U.S. Adult: Hepatitis C Screening Steps Clinicians Need
Every adult in the United States should get a one-time hepatitis C test, no risk factors required, and every pregnant person should be screened during each pregnancy, according to both the CDC and the USPSTF. The standard workup starts with an HCV antibody test; if that comes back reactive, the lab should automatically run HCV RNA (a NAT test) on the same sample. Anyone who asks for a hepatitis C test should get one, and people with ongoing risk factors need periodic retesting, not just a single screen.
TL;DR: Most adults should receive a one-time hepatitis C antibody test, with reflex RNA testing if reactive, as it accurately detects current or past infection. Pregnant individuals need screening during each pregnancy to account for new exposures, with additional testing for infants born to HCV-positive mothers. People with ongoing risk factors like injection drug use or HIV require retesting every year, not just a single screen, to catch new infections. Direct-acting antiviral therapy cures most cases of hepatitis C within 8 to 12 weeks, making early diagnosis and linkage to care crucial for successful treatment. Practices must confirm whether their labs automatically run reflex RNA tests and streamline workflows to prevent patients from falling through the cracks.
Table of Contents
- What Do the Hepatitis C Screening Guidelines Say About Who Needs Testing?
- How Is Hepatitis C Screened? The Testing Algorithm Explained
- What Do Your Hepatitis C Test Results Actually Mean?
- Special Cases: Pregnancy, Infants, Dialysis, and Occupational Exposure
- How Can Clinicians Put HCV Screening Guidelines Into Practice?
- A Gastroenterology Practice’s Take on Making Screening Actually Work
- Sources
- FAQ
What Do the Hepatitis C Screening Guidelines Say About Who Needs Testing?
The core message from the CDC and USPSTF is simple: screen every adult once, screen every pregnancy, and screen certain groups more often, highlighting the general health screening benefits you can actually use to improve patient outcomes. The USPSTF gives this a Grade B recommendation, meaning there’s high certainty the benefit is moderate to substantial for adults 18 and older. That grade matters practically, because it means insurers are required to cover the test with no copay under the Affordable Care Act’s preventive services provision.
The universal screening approach exists because hepatitis C often has no symptoms for years, sometimes decades, while it quietly damages the liver. Risk-based screening alone kept missing people who didn’t fit the old profile of a person who injects drugs. A one-time screen for everyone catches those cases.
There’s technically an exception: settings can skip universal screening if they can document that HCV RNA prevalence among their patients is under 0.1%. In practice, this exception almost never applies. Proving a rate that low takes a large, carefully sampled patient population, often several hundred people tested with rigorous methodology, and most primary care and gastroenterology practices have neither the data nor the incentive to try. Universal screening is simply the more practical default.
Pregnancy gets its own recommendation, separate from the one-time adult screen. The CDC recommends testing every pregnant person during every pregnancy, not just the first one. A prior negative result doesn’t carry forward, since new exposures can happen between pregnancies. This also sets up the pediatric follow-up chain: a positive maternal result flags the infant for RNA testing after birth.
Beyond the universal recommendation, several groups need testing on top of or instead of the one-time screen, either because their risk is ongoing or because a specific event calls for a check:
- People who currently inject drugs or have ever injected drugs, even once, years ago
- People living with HIV
- People on hemodialysis, who face ongoing exposure risk through shared equipment and vascular access
- Anyone who received a blood transfusion or organ transplant before July 1992, or clotting factor concentrates before 1987
- Healthcare and public safety workers after a needlestick or other occupational exposure to HCV-positive blood
- Infants born to a parent who tested positive for HCV during pregnancy
- Anyone with elevated liver enzymes of unclear cause, since undiagnosed HCV is a common culprit
For people with ongoing injection drug use, the guidance calls for annual retesting, not a one-time check. The logic is straightforward: risk that continues means exposure that continues, and a single negative test three years ago tells you nothing about last month.
One policy point clinicians sometimes overlook: if a patient asks for an HCV test, they should get one. You don’t need to interrogate their risk factors or make them justify the request. A patient’s own sense that they might be at risk, even one they can’t fully articulate, is reason enough to test.
How Is Hepatitis C Screened? The Testing Algorithm Explained
Hepatitis C screening runs on a two-step logic: antibody first, RNA to confirm. An FDA-approved HCV antibody assay detects whether the immune system has ever encountered the virus. A reactive antibody result doesn’t mean active infection. It means exposure at some point, current or past, cleared or chronic. That’s why the next step matters so much.
When the antibody test is reactive, the lab should automatically run HCV RNA (nucleic acid testing, or NAT) on the same specimen without waiting for a second office visit or a new order. This is called reflex testing, and it’s the biggest efficiency gain in modern HCV diagnosis. Detectable RNA confirms current infection. Undetectable RNA after a reactive antibody usually means the person cleared a past infection on their own or was successfully treated, and they’re not currently infected.
There are situations where you shouldn’t wait for antibody results at all, or shouldn’t trust a negative one:
- Recent exposure within the past six months. Antibodies can take 8 to 11 weeks to become detectable after exposure, while HCV RNA is often detectable within 1 to 2 weeks. A needlestick injury three weeks ago with a negative antibody test tells you almost nothing yet.
- Immunocompromised patients, including those on dialysis or with advanced HIV, who may never mount a strong antibody response even when infected.
- Suspected acute infection with symptoms like jaundice or unexplained fatigue in someone with a plausible exposure history.
In these cases, order HCV RNA directly rather than waiting on the antibody result.
Labs distinguish between qualitative RNA tests (detected or not detected) and quantitative tests (viral load, reported in IU/mL). For diagnosis, either works, but the assay needs a lower limit of detection around 25 IU/mL or below to reliably catch low-level viremia. Quantitative results become more important later, during treatment monitoring, when a clinician needs to track whether viral load is dropping.
Point-of-care rapid antibody tests, the finger-stick kind used in outreach settings and some urgent care clinics, offer real value for reaching people who won’t come back for a second visit. Results come in 20 minutes. The tradeoff is that a reactive rapid test still needs confirmatory RNA testing through a standard lab, since fingerstick assays aren’t designed to distinguish current infection from past exposure.
Pro Tip: Ask your lab, in writing, whether they run reflex RNA automatically on reactive antibody results. Some labs default to it and others require a specific order code. Finding this out before you need it saves a patient from a second blood draw and a two-week delay.
What Do Your Hepatitis C Test Results Actually Mean?
A nonreactive antibody result generally means no current or past infection, assuming enough time has passed since any possible exposure. If the test happened within the antibody window period, a repeat test later is worth considering for anyone with a specific recent exposure.
A reactive antibody with undetectable RNA means past infection that resolved, either spontaneously or through prior treatment. No current treatment is needed, though some clinicians recommend documenting this clearly in the chart, since a reactive antibody can otherwise cause confusion on future screens.
Detectable HCV RNA means current infection, and it calls for a specific sequence of next steps:
- Counsel the patient on what the diagnosis means: hepatitis C is treatable and, for most people, curable. This isn’t the same conversation it was fifteen years ago, and patients often carry outdated fear about it.
- Run a baseline evaluation, including liver function tests and an assessment of fibrosis stage, to understand how far the disease has progressed.
- Check vaccination status for hepatitis A and B and vaccinate if the patient isn’t already immune, since a second liver infection on top of HCV raises the risk of serious complications.
- Screen for alcohol use and counsel on reducing intake, since alcohol accelerates liver damage in someone with active HCV.
- Test for HIV if it hasn’t been done recently, given the overlapping risk factors and transmission routes.
- Arrange linkage to care, ideally through a direct, scheduled handoff to a gastroenterologist, hepatologist, or HCV treatment specialist rather than a general referral slip.
That last step is where a lot of diagnoses quietly stall. One study of Medicaid patients found that only 23% of people with a positive HCV RNA test started DAA treatment within 360 days of diagnosis. Insurance authorization delays, transportation barriers, and patients simply falling through the cracks between a primary care diagnosis and a specialist appointment all play a part. A warm handoff, meaning the diagnosing clinician books the specialist appointment directly rather than handing the patient a phone number, measurably improves the odds that treatment actually starts.
Direct-acting antiviral (DAA) therapy is the standard treatment now, and it’s a different world from the interferon era. Most regimens run 8 to 12 weeks and cure the large majority of patients with minimal side effects. AASLD/IDSA guidance covers regimen selection based on genotype, prior treatment history, and liver disease stage, along with the pretreatment labs needed before starting.
Special Cases: Pregnancy, Infants, Dialysis, and Occupational Exposure
Routine adult screening rules bend in a few predictable ways once you’re dealing with pregnancy, infancy, immune suppression, or a specific exposure event.
Pregnancy gets tested every time, as covered above, but the timing matters for coordination with obstetrics. Testing typically happens at the first prenatal visit alongside other standard bloodwork, which gives enough lead time to plan delivery-related precautions and set up pediatric follow-up if the result is positive.
Infants born to an HCV-positive parent need HCV RNA testing at 2 to 6 months of age, not antibody testing. Maternal antibodies cross the placenta and linger in an infant’s blood for well over a year, so an antibody test in a young infant mostly measures the mother’s immune history, not the baby’s. If RNA comes back detectable, the infant needs referral to a pediatric hepatologist or pediatric HCV specialist for ongoing management.
Dialysis patients face a real ongoing exposure risk through shared equipment and close contact with other patients in a treatment setting, even with strong infection control practices. Facilities generally test on admission and then periodically, often built into routine dialysis center protocols.
Immunocompromised patients, including transplant recipients and those on immunosuppressive therapy, sometimes need RNA-based testing rather than antibody testing even outside the recent-exposure window, since a suppressed immune system may never generate a detectable antibody response.
Occupational exposures, like a needlestick from an HCV-positive source, call for a specific testing schedule:
- Baseline antibody and RNA testing on the exposed worker as soon as possible after the incident
- Follow-up RNA testing around 3 to 6 weeks post-exposure, since RNA appears faster than antibodies
- A final antibody check around 4 to 6 months to close out the workup
Reinfection is a real possibility for anyone with ongoing risk factors even after a cure. Someone treated successfully for HCV who continues injecting drugs, for instance, needs the same periodic retesting recommended for any person with ongoing risk, since a cured infection provides no lasting immunity against catching it again.
How Can Clinicians Put HCV Screening Guidelines Into Practice?
Guidelines are only as good as the workflow behind them. The biggest practical lever is confirming, in advance, whether your lab reflexes automatically from antibody to RNA. If it doesn’t, you have two workable options: order both tests up front at the initial visit, explaining to the patient that the RNA result will simply come back negative if the antibody isn’t reactive, or build a hard follow-up step into your workflow so a reactive antibody never sits unconfirmed for weeks.
Collecting specimens in a single visit whenever possible cuts down on one of the biggest points of patient loss. Every extra visit required between screening and diagnosis is a chance for someone to not come back, whether from work conflicts, transportation, or simply forgetting.
A few workflow habits make a measurable difference:
- Build an opt-out prompt into the EHR so HCV screening shows up automatically for eligible patients rather than depending on a clinician remembering
- Confirm your billing codes ahead of time so preventive screening is coded correctly and patients aren’t unexpectedly billed
- Know your state’s reporting requirements, since HCV diagnoses are reportable to public health departments in most jurisdictions
- Keep a short list of specialists or navigators you can call directly for a warm handoff rather than a cold referral
Pro Tip: If your practice sees a diagnosis and the patient doesn’t have a clear path to a specialist that week, call the specialist’s office yourself while the patient is still in the room. A same-day scheduled appointment, even a few weeks out, does more for treatment initiation than any pamphlet.
Patient navigation matters just as much for people without insurance or with high-deductible plans. Manufacturer assistance programs and state-level Ryan White or Hepatitis programs can cover DAA costs for qualifying patients, and knowing which forms to hand a patient at the moment of diagnosis, rather than after they’ve already given up, changes outcomes. Practices that treat prevention seriously, the same logic behind routine colon cancer screening, tend to catch and treat HCV earlier for the same reason: they’ve built the systems that don’t rely on the patient chasing down their own diagnosis.
A Gastroenterology Practice’s Take on Making Screening Actually Work
National guidelines are clear on paper. The gap is always in execution, and that’s where most practices lose patients. Precision Digestive Health treats reflex RNA testing as a default, not an afterthought, because a patient who leaves an appointment with an unresolved reactive antibody result rarely comes back for the second draw on their own.
Communication matters just as much as the lab logic. Patients hear “hepatitis C” and often think of a decades-old diagnosis with grim odds, not a condition curable in 8 to 12 weeks with modern therapy. Framing a positive result honestly, and immediately pairing it with next steps, does more for follow-through than any pamphlet. For pregnant patients, that means an early conversation with obstetrics about testing timing and what a positive result means for the infant’s follow-up plan, so nobody is scrambling after delivery.
Screening only matters if it leads somewhere. If you’re due for a one-time HCV screen, or you have liver enzyme results that don’t add up, scheduling an evaluation is the next right step, and Precision Digestive Health’s liver disease management services are built for exactly this handoff from diagnosis to treatment.
— Precision Digestive Health
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
Sources
- HCV Testing and Linkage to Care – HCV Guidance
- Hepatitis C Virus Screening, Testing, and Diagnosis in Adults (NCBI Bookshelf)
FAQ
Can you have hepatitis C for 20 years and not know it?
Yes. Hepatitis C often causes no symptoms for years or even decades while it damages the liver, which is exactly why the CDC recommends a one-time screen for every adult rather than waiting for symptoms to appear.
What are the CDC guidelines for hepatitis B testing, and are they the same as for hepatitis C?
Hepatitis B and C have separate CDC screening recommendations, and this article covers hepatitis C guidance specifically. For hepatitis C, the CDC recommends one-time universal screening for all adults 18 and older plus screening during every pregnancy, using an antibody test followed by reflex RNA testing when reactive.
Can you test for hepatitis C after two months?
An antibody test at two months post-exposure may still be too early, since antibodies can take 8 to 11 weeks to become detectable. HCV RNA testing, by contrast, can typically detect infection within 1 to 2 weeks of exposure, so RNA testing is the better choice that soon after a known exposure.
Do I need to explain my risk factors to get tested for hepatitis C?
No. Anyone who requests an HCV test should be offered one regardless of disclosed risk factors, and universal screening guidelines mean every adult qualifies for a one-time test without justification.
How often should someone with ongoing risk factors get retested?
People with ongoing injection drug use should get tested annually, while other ongoing-risk groups, such as dialysis patients, typically follow a periodic retesting schedule set by their care team based on continued exposure risk.
